Inovio Pharmaceuticals Inc (INO)

[Lakers_w]

3/19/22 Lancet: The primary objective of the Sisonke study was to assess the effectiveness of the single-dose Ad26.COV2.S vaccine to prevent COVID-19-related admission to hospital (hereafter referred to as hospitalisation), hospitalisation requiring critical care unit (CCU) or intensive care unit (ICU) admission, and death in health-care workers. Additionally, with a large proportion of the population living with HIV in South Africa, in post-hoc analyses, we were able to assess vaccine effectiveness among health-care workers living with HIV.

During the course of the study, the beta (B.1.351) and then the delta (B.1.617.2) SARS-CoV-2 variants of concerns were dominant, and vaccine effectiveness remained consistent (for scheme A plus B vaccine effectiveness against COVID-19-related hospital admission during beta wave was 62% [95% CI 42–76] and during delta wave was 67% [62–71], and vaccine effectiveness against COVID-19-related death during beta wave was 86% [57–100] and during delta wave was 82% [74–89]).
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00007-1/fulltext